Belfast, United Kingdom

Jill Caswell

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fusion Antibodies Limited. Active years: 2014.


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jill Caswell

Introduction

Jill Caswell is a prominent inventor based in Belfast, GB. She has made significant strides in the field of biotechnology, particularly in the development of therapeutic antibodies. Her work focuses on addressing critical health issues, including cancer and diseases associated with angiogenesis.

Latest Patents

Jill holds a patent for "Anti-AREG/HB-EGF antibodies and treatment." This patent describes cross-specific antibody molecules that exhibit binding specificity for both AREG and HB-EGF. These innovative antibody molecules have potential applications in the treatment of cancer and related diseases, showcasing her commitment to advancing medical science.

Career Highlights

Throughout her career, Jill has demonstrated exceptional expertise in her field. She is currently associated with Fusion Antibodies Limited, where she continues to contribute to groundbreaking research and development. Her work has not only advanced scientific knowledge but also holds promise for improving patient outcomes.

Collaborations

Jill collaborates with talented professionals in her field, including Declan Doherty and Thomas Jaquin. These partnerships enhance her research efforts and foster innovation within the biotechnology sector.

Conclusion

Jill Caswell's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to inspire advancements in medical treatments and showcases the importance of innovation in addressing global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…